INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics
INMB Price/Volume Stats
| Current price | $10.43 | 52-week high | $14.74 |
| Prev. close | $10.62 | 52-week low | $6.50 |
| Day low | $10.04 | Volume | 35,147 |
| Day high | $10.61 | Avg. volume | 95,877 |
| 50-day MA | $11.44 | Dividend yield | N/A |
| 200-day MA | $9.62 | Market Cap | 189.86M |
INMB Stock Price Chart Interactive Chart >
INmune Bio Inc. - Common stock (INMB) Company Bio
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Latest INMB News From Around the Web
Below are the latest news stories about INMUNE BIO INC that investors may wish to consider to help them evaluate INMB as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! |
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDAEnrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023. Boca R |
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer SymposiumINB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the tumor killing immunology of the tumor microenvironment. Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is prese |
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s DiseaseBoca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spa |
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just BeginningBiogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started. |
INMB Price Returns
| 1-mo | -12.21% |
| 3-mo | -13.66% |
| 6-mo | 50.07% |
| 1-year | 49.43% |
| 3-year | -12.21% |
| 5-year | 0.29% |
| YTD | -7.37% |
| 2023 | 77.60% |
| 2022 | -37.84% |
| 2021 | -40.77% |
| 2020 | 196.90% |
| 2019 | N/A |
Loading social stream, please wait...